Tasly Holding Group
2001
FOUNDED
PUBLIC
STATUS
5K-10K
EMPLOYEES
600535
STOCK SYMBOL
16
INVESTMENTS
$3.21
SHARE PRICE
(As of Tuesday Closing)
Description
Manufacturer of pharmaceutical products created for treatment of coronary heart disease. The company's pharmaceuticals manufactured using ground-breaking technology and cutting-edge science enabling patients to relieve headache, as well as bupleurum pills, huoxiangzhengqi pills, pills for stomach diseases and andrographolide pills.
Website
Formerly Known As
Tianjin Tasly Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHG
Primary Office
- Tasly Modern TCM Building No. 2
- Pujihe East Road Beichen District
- Tianijn, 300410
- China
+86 00000000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Tasly Holding Group’s full profile, request a free trial.
Tasly Holding Group Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $2.89 - $5.27 | $4.84B | $3.17 | $0.14 | 11.8M | 1.51B |
Tasly Holding Group Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 9,146,219 | 7,083,261 | 6,906,414 | 7,419,569 |
| Revenue | 2,520,492 | 2,381,514 | 2,093,657 | 2,105,439 |
| EBITDA | 270,422 | 353,271 | 270,984 | 331,094 |
| Net Income | 215,828 | 203,692 | 176,618 | 235,446 |
| Total Assets | 3,621,389 | 3,298,032 | 2,466,412 | 2,374,171 |
| Total Debt | 1,510,978 | 1,379,320 | 608,342 | 738,826 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Tasly Holding Group Investments & Acquisitions (16)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 14-Aug-2018 | 00000 00000 00 | 0000 | Other Devices and Supplies | |
| 000000000 00000 (0 | 10-Jul-2018 | 000000000000000000 | 0000 | Pharmaceuticals | 0000000 000 |
| 0-000 000000000 | 29-Jun-2018 | 00000 00000 00 | 00000 | Drug Discovery | 0000000 000 |
| 00000000 | 10-Jan-2018 | 00000 00000 00 | Social/Platform Software | ||
| Genova Biotech | 10-Dec-2017 | Corporate | 0000 | Biotechnology |
Tasly Holding Group Exits (5)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 000000000 | 23-Mar-2017 | 00 000000000000000 | Completed |
|
|
| 00000000000 000000 | 23-Mar-2017 | 00 000000000000000 | 00000 | Completed |
|
| 00000000 | 03-Jan-2017 | 00000 00000 00 | 00000 | Completed |
|
| 00000000 | 02-Sep-2015 | 00000 00000 00 | 0000 | Completed |
|
| Tianzhenshi Biotechnology Company | Early Stage VC | Completed |
|
Tasly Holding Group Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000 0000000000 | Pharmaceuticals | Tianjin, China | 0000 |
Tasly Holding Group Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Tasly Holding Group‘s full profile, request access.
Request full access to PitchBookTasly Holding Group Executive Team (1)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Kaijing Yan | Founder, Chairman & Chief Executive Officer |
Tasly Holding Group Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0000000 000 | Tasly Holding Group | Founder, Chairman & Chief Executive Officer | 000 0000 |